Biofil Chemicals & Pharmaceuticals share news and announcements
NSE: BIOFILCHEMBSE: 524396Pharmaceuticals & BiotechnologySmall Cap
Last close ₹28.86down ₹0.18 (0.62%)BSE ₹28.17
Share price at the NSE close on 23 Oct 2026. Previous close ₹29.04.
52-week range of traded prices to 23 Oct 2026
₹25.60Low, 30 Mar 2026₹46.34High, 3 Feb 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹47 Cr3,363rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 97.0
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 May 2026
- 2.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 2.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 2.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 May 2026
- 0.14
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,19251.9% delivered
Biofil Chemicals & Pharmaceuticals share news and announcements
403 announcements, routine notices left out, newest first. Page 2 of 9.
Mar 2025
Feb 2025
19 Feb · Updates
17 Feb · Meeting
11 Feb · Board meeting
Dec 2024
Nov 2024
14 Nov · Board meeting
Oct 2024
Sep 2024
14 Sep · Disclosure of material issue
14 Sep · Management
Aug 2024
13 Aug · Disclosure of material issue
13 Aug · Board meeting
Jul 2024
May 2024
30 May · Management
30 May · Management
30 May · Board meeting
Mar 2024
29 Mar · Management
11 Mar · Legal
Exchange has sought clarification from Biofil Chemicals & Pharmaceuticals Limited with respect to announcement dated 06-Feb-2024, regarding Board meeting held on February 06, 2024.". On basis of above the Company is required to clarify following: 1. The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year;2. Date on which the agreement for sale has been entered into;3. The expected date of completion of sale/disposal;4. Consideration received from such sale/disposal;5. Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof.6. Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";7. Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.The response of the Company is awaited.
Feb 2024
9 Feb · Meeting
6 Feb · Board meeting
Jan 2024
Nov 2023
9 Nov · Board meeting
9 Nov · Board meeting